Methods of inhibiting protein tyrosine kinase activity

A method of inhibiting angiogenesis and/or treating a disease responsive to inhibition of kinase activity and/or treating a cell proliferative disease and/or treating an opthalmic disease, condition or disorder in patient in need thereof, the method comprising administering to said patient a therapeutically effective amount of a compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein,
• D is selected from the group consisting of an aromatic, heteroaromatic, cycloalkyl or heterocyclic ring system, each of which is substituted with 1 to 5 independently selected R38;
• M is
• wherein
• * represents the point of attachment to D;
• and
• † represents the point of attachment to Z;
• Z is —O—;
• Ar is a 5 to 7 membered aromatic ring system, which is optionally substituted with 0 to 4 R2 groups;
• and
• G is selected from the group consisting of
• wherein
• each R38 is —C1-C6alkyl-heterocycle, wherein said heterocycle is optionally substituted with halo, hydroxy, oxo, nitro, halohydrocarbyl, hydrocarbyl, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups, and;
• R2 at each occurrence is independently selected from —H and halogen;
• each R3 is independently selected from the group consisting of —H and R4;
• R4 is (C1-C6)alkyl;
• each R13 is independently selected from the group consisting of —H, —C(O)NR3R3 and C1-C6 alkyl;
• Q is a three- to ten-membered ring system, optionally substituted with between zero and four of R20;
• each R20 is independently selected from the group consisting of —H, halogen, trihalomethyl, —OR3, —S(O)0-2R3, —S(O)2NR3R3, —C(O)OR3, —C(O)NR3R3, —(CH2)0-5(heteroaryl), C1-C6 alkyl, —(CH2)nP(═O)(C1-C6alkyl)2, wherein n is an integer ranging from 0 to 6.